• Powell-WileyTM
• Pear tree P
• Burke LE
• et al.

Obesity and Cardiovascular Disease: A Scientific Statement from the American Heart Association.

Circulation. 2021; 143: e984-1010

• Hales CM
• CD Fryer
• Carroll MD
• Freedman DS
• Ogden CL

Trends in obesity and the prevalence of severe obesity among U.S. youth and adults by sex and age, 2007-2008 to 2015-2016.

JAMA. 2018; 319: 1723-1725

• Hales CM
• Carroll MD
• CD Fryer
• Ogden CL

Prevalence of obesity and severe obesity in adults: United States, 2017-2018.

NCHS Data Sheet. 2020; 360: 1-8

Fifty Years of Behavioral / Lifestyle Interventions for Overweight and Obesity: Where Are We and Where Are We Going ?.

Obesity (Silver Spring). 2017; 25: 1867-1875

• Montesi L
• El Ghoch M
• Brodosi L
• Calugi S
• Marchesini G
• Grave R slab

Maintaining long-term weight loss for obesity: a multidisciplinary approach.

Diabetes Metab Syndr Obes. 2016; 9: 37-46

• RR wing
• Bolin P
• Brancati FL
• et al.

Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes.

N Engl J Med. 2013; 369: 145-154

• Neeland IJ
• Turer AT
• Ayers CR
• et al.

Dysfunctional adiposity and risk of prediabetes and type 2 diabetes in obese adults.

JAMA. 2012; 308: 1150-1159

• Neeland IJ
• Turer AT
• Ayers CR
• et al.

Distribution of body fat and cardiovascular disease in obese adults.

J Am Coll Cardiol. 2015 ; 65: 2150-2151

• Neeland IJ
• Ayers CR
• Rohatgi AK
• et al.

Associations of visceral and abdominal subcutaneous adipose tissue with markers of cardiac and metabolic risk in obese adults.

Obesity (Silver Spring). 2013; 21: E439-E447

• CS Fox
• Massaro JM
• Hoffmann U
• et al.

Visceral and subcutaneous fatty tissue compartments of the abdomen: association with metabolic risk factors in the Framingham Heart Study.

Circulation. 2007; 116: 39-48

• Liu J
• CS Fox
• Hickson DA
• et al.

Impact of abdominal, visceral and subcutaneous adipose tissue on cardiometabolic risk factors: the Jackson Heart Study.

J Clin Endocrinol Metab. 2010; 95: 5419-5426

• Boyko EJ
• Fujimoto WY
• Leonetti DL
• Newell-Morris L

Visceral adiposity and the risk of type 2 diabetes: a prospective study in Japanese Americans.

Diabetic treatments. 2000; 23: 465-471

• Khera R
• Mourad MH
• Chandar AK
• et al.

Association of pharmacological treatments for obesity with weight loss and adverse events: a systematic review and meta-analysis.

JAMA. 2016; 315: 2424-2434

• Jensen MD
• Ryan dh
• CM Apovian
• et al.

2013 AHA / ACC / TOS Guidelines for the Management of Overweight and Obesity in Adults: Report of the American College of Cardiology / American Heart Association Task Force on Practice Guidelines and The Obesity Society.

Circulation. 2014 ; 129: S102-S138

• CM Apovian
• Aronne LJ
• Bessesen DH
• et al.

Pharmacological management of obesity: clinical practice guide from the Endocrine Society.

J Clin Endocrinol Metab. 2015 ; 100: 342-362

• Rao S
• Pandey A
• Garg S
• et al.

Effect of exercise and pharmacological interventions on visceral adiposity: a systematic review and meta-analysis of long-term randomized controlled trials.

Mayo Clin Proc. 2019; 94: 211-224

• Bizino MB
• Jazet IM
• by Heer P
• et al.

Randomized, placebo-controlled trial of liraglutide on magnetic resonance parameters in people with type 2 diabetes: a pre-specified secondary study on ectopic fat accumulation.

Diabetology. 2020; 63: 65-74

• van Eyk HJ
• Païman EHM
• Bizino MB
• et al.

A randomized, double-blind, placebo-controlled trial to evaluate the effect of liraglutide on ectopic fat accumulation in South Asian type 2 diabetic patients.

Cardiovascular Diabetol. 2019; 18: 87

• Ishii S
• Nagai Y
• Sada Y
• et al.

Liraglutide reduces visceral and intrahepatic fat without significant loss of muscle mass in obese patients with type 2 diabetes: a prospective case series.

J Clin Med Res. 2019; 11: 219-224

• Mehta A
• Marso SP
• Neeland IJ

Liraglutide for weight management: a critical review of the evidence.

Obes Sci Pract. 2017; 3: 3-14

• Pi-Sunyer X
• Astrup A
• Fujioka K
• et al.

A randomized controlled trial of 3.0 mg of liraglutide in weight management.

N Engl J Med. 2015 ; 373: 11-22

• Davies MJ
• Bergenstal R
• Bode B
• et al.

Effectiveness of liraglutide for weight loss in patients with type 2 diabetes: the randomized clinical trial in diabetes SCALE.

JAMA. 2015 ; 314: 687-699

• AT Wadden
• Hollander P
• Klein S
• et al.

Weight maintenance and additional weight loss with liraglutide after low-calorie diet-induced weight loss: the randomized SCALE Maintenance study.

Int J Obes. 2013; 37: 1443-1451

• Marso SP
• Daniels GH
• Brown-Frandsen K
• et al.

Liraglutide and cardiovascular results in type 2 diabetes.

N Engl J Med. 2016; 375: 311-322

• JB Bus
• SC bath
• Mann JFE
• et al.

Reduction of cardiovascular risk with liraglutide: an exploratory mediating analysis of the LEADER trial.

Diabetic treatments. 2020; 43: 1546-1552

• Astrup A
• Carraro R
• Thinner N
• et al.

Safety, tolerance and sustained weight loss over 2 years with the once-daily human GLP-1 analogue, liraglutide.

Int J Obes. 2012; 36: 843-854

Saxenda from Novo Nordisk remains the best obesity treatment in the world.

• Grundy SM
• Cleeman ji
• Daniels SR
• et al.

Diagnosis and management of metabolic syndrome: a scientific statement from the American Heart Association / National Heart, Lung, and Blood Institute.

Circulation. 2005; 112: 2735-2752

Human energy needs: report of a joint FAO / WHO / UNU expert consultation.

Nutr Bull food. 2005; 26: 166

• J west
• Dahlqvist Leinhard O
• Romu T
• et al.

Feasibility of MRI-based analysis of body composition in large-scale population studies.

PLoS One. 2016; 11e0163332

• Borga M
• Thomas EL
• Romu T
• et al.

Validation of a rapid method for quantifying intra-abdominal and subcutaneous adipose tissue for large-scale human studies.

Biomed NMR. 2015 ; 28: 1747-1753

• Karlsson A
• Rosander J
• Romu T
• et al.

Automatic and quantitative evaluation of regional muscle volume by multi-atlas segmentation using whole body water-fat MRI.

J Magn Reson Imaging. 2015 ; 41: 1558-1569

• J west
• Romu T
• Thorell S
• et al.

Accuracy of body composition measurements by MRI of postmenopausal women.

PLoS One. 2018; 13e0192495

• Borga M
• Ahlgren A
• Romu T
• Widholm P
• Dahlqvist Leinhard O
• J west

Reproducibility and repeatability of MRI body composition analysis.

Magn Reson Med. 2020; 84: 3146-3156

• Astrup A
• Rössner S
• Van Gaal L
• et al.

Effects of liraglutide in the treatment of obesity: randomized, double-blind, placebo-controlled study.

Lancet. 2009; 374: 1606-1616

• Santilli F
• Simeone PG
• Guagnano MT
• et al.

Effects of liraglutide on weight loss, fat distribution and β cell function in obese subjects with prediabetes or early type 2 diabetes.

Diabetic treatments. 2017; 40: 1556-1564

• Jendle J
• Nauck MA
• Matthews DR
• et al.

Weight loss with liraglutide, a human glucagon-like peptide-1 analogue given once daily for the treatment of type 2 diabetes as monotherapy or added to metformin, results primarily from reduction in adipose tissue.

Diabetes Obes Metab. 2009; 11: 1163-1172

• Wilding JPH
• Batterham RL
• Calanna S
• et al.

Semaglutide once a week in overweight or obese adults.

N Engl J Med. 2021; 384: 989-1002

• Shin J
• Syme C
• Wang D
• et al.

New genetic locus of visceral fat and systemic inflammation.

J Clin Endocrinol Metab. 2019; 104: 3735-3742

• Ridker PM
• Everett BM
• Thuren T
• et al.

Anti-inflammatory therapy with canakinumab for atherosclerotic disease.

N Engl J Med. 2017; 377: 1119-1131

• Nidorf SM
• ATL Fiolet
• Mosterd A
• et al.

Colchicine in patients with chronic coronary artery disease.

N Engl J Med. 2020; 383: 1838-1847

• Matikainen N
• Söderlund S
• Björnson E
• et al.

Liraglutide Treatment Improves Postprandial Lipid Metabolism and Cardiometabolic Risk Factors in Men With Well-Controlled Type 2 Diabetes: A Single-Center Randomized Controlled Study.

Diabetes Obes Metab. 2019; 21: 84-94

• Taher J
• Baker C
• Alvares D
• Ijaz L
• Hussein M
• Adeli K

GLP-2 deregulates hepatic lipoprotein metabolism, inducing hepatic steatosis and overproduction of VLDL in hamsters and male mice.

Endocrinology. 2018; 159: 3340-3350

• Hussein A
• Ballantyne CM
• Said A
• Virani SS

Triglycerides and risk reduction of ASCVD: recent perspectives and future directions.

Curr Atheroscler Rep. 2020; 22: 25

• Nielsen S
• Guo Z
• Johnson CM
• Hensrud DD
• Jensen MD

Splanchnic lipolysis in human obesity.

J Clin Invest. 2004 ; 113: 1582-1588

Body fat distribution and cardiovascular disease risk: an update.

Circulation. 2012; 126: 1301-1313

• Anholm C
• Kumarathurai P
• Pedersen LR
• et al.

Liraglutide in combination with metformin may improve atherogenic lipid profile and decrease C-reactive protein level in statin-treated patients with newly diagnosed coronary heart disease and type 2 diabetes: a randomized trial.

Atherosclerosis. 2019; 288: 60-66

• Burhans MS
• Balou N
• Schmidt KA
• et al.

Impact of the analytical approach on the reliability of the MRI assessment of hepatic fat content.

Curr Dev Nutr. 2020; 4nzaa171

• Berkowitz RI
• AT Wadden
• Tershakovec AM
• Cronquist JL

Behavioral therapy and sibutramine for the treatment of obesity in adolescents: a randomized controlled trial.

JAMA. 2003; 289: 1805-1812